Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.52B 16.16B 14.95B 28.37B 1,912B 28.85B 193B 75.84B 939B 75.18B 73.55B 3,251B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.89B 17.42B 16.12B 30.6B 2,061B 31.11B 209B 81.79B 1,012B 81.07B 79.32B 3,506B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+3.08%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
120.76
10 years 11.96
Extreme 11.96
159.54
Date Insider Type Main position Quantity % Market Cap.
Mar. 22Free

Executive/Senior Manager

199,374 0.1044%
Mar. 22Issuer sale

Director

57,962 0.0304%
Mar. 22Free

Chief Financial Officer

261,465 0.1370%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+95.95%+15.83% 20.03B
+5.67%+3.89%+118.98%+135.22% 4.48B
+8.13%+2.88%+82.73%+233.33% 3.23B
+1.31%-5.70%-29.84%-41.05% 1.94B
+2.10%+1.39%+119.60%-50.28% 1.91B
+5.66%-0.27%+43.54%+199.79% 1.42B
-3.54%-5.05%-12.38%+40.25% 852M
+3.65%-1.16%+116.30%-51.11% 850M
+1.15%-14.62%-4.57% - 447M
-1.21%-2.16%-37.45%-18.98% 479M
Average +2.39%-4.31%+49.29%+51.45% 3.56B
Weighted average by Cap. +2.39%-2.23%+84.83%+50.20%

Financials

2024 2025
Net sales 2.76B 2.41B 2.23B 2.06B 3.91B 263B 3.97B 26.65B 10.45B 129B 10.36B 10.13B 448B 3.25B 2.84B 2.62B 2.42B 4.6B 310B 4.68B 31.37B 12.3B 152B 12.19B 11.93B 527B
Net income -1.03B -900M -830M -768M -1.46B -98.21B -1.48B -9.94B -3.9B -48.23B -3.86B -3.78B -167B -208M -182M -168M -155M -295M -19.85B -300M -2.01B -788M -9.75B -781M -764M -33.76B
Net Debt 1.74B 1.52B 1.4B 1.3B 2.46B 166B 2.5B 16.79B 6.58B 81.45B 6.52B 6.38B 282B 1.57B 1.37B 1.27B 1.17B 2.22B 150B 2.26B 15.17B 5.95B 73.6B 5.89B 5.77B 255B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock